- Home
- PRQR vs VNDA Comparison
PRQR vs VNDA Comparison
Compare PRQR & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- VNDA
- Stock Information
- Founded
- PRQR 2012
- VNDA 2002
- Country
- PRQR Netherlands
- VNDA United States
- Employees
- PRQR N/A
- VNDA N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- VNDA Health Care
- Exchange
- PRQR Nasdaq
- VNDA Nasdaq
- Market Cap
- PRQR 232.8M
- VNDA 249.4M
- IPO Year
- PRQR 2014
- VNDA 2006
- Fundamental
- Price
- PRQR $2.15
- VNDA $4.52
- Analyst Decision
- PRQR Strong Buy
- VNDA Strong Buy
- Analyst Count
- PRQR 8
- VNDA 2
- Target Price
- PRQR $8.88
- VNDA $16.50
- AVG Volume (30 Days)
- PRQR 368.1K
- VNDA 346.2K
- Earning Date
- PRQR 11-06-2025
- VNDA 11-05-2025
- Dividend Yield
- PRQR N/A
- VNDA N/A
- EPS Growth
- PRQR N/A
- VNDA N/A
- EPS
- PRQR N/A
- VNDA N/A
- Revenue
- PRQR $20,129,184.00
- VNDA $203,467,000.00
- Revenue This Year
- PRQR N/A
- VNDA $15.45
- Revenue Next Year
- PRQR N/A
- VNDA $37.82
- P/E Ratio
- PRQR N/A
- VNDA N/A
- Revenue Growth
- PRQR 8.65
- VNDA 11.78
- 52 Week Low
- PRQR $1.07
- VNDA $3.81
- 52 Week High
- PRQR $4.62
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- PRQR 49.40
- VNDA 49.04
- Support Level
- PRQR $1.91
- VNDA $4.36
- Resistance Level
- PRQR $2.50
- VNDA $4.64
- Average True Range (ATR)
- PRQR 0.16
- VNDA 0.15
- MACD
- PRQR -0.03
- VNDA -0.02
- Stochastic Oscillator
- PRQR 44.07
- VNDA 27.68
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.